Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy

Table 3 Baseline characteristics of the cancer-dead and survival patients

	Cancer death	Survival	P value
Total (n)	118	132	–
Age (n)	64.2 ± 5.5	64.7 ± 6.1	0.573
Gender (n)
Female	23	30	0.532
Male	95	102
Smoking history (n)
Non-smoker	47	60	0.370
Smoker	71	72
Performance status
0–1	98	120	0.063
2	20	12
Tumor grade (n)
High-middle	83	110	0.014
Low	35	22
Tumor stage (n)
LD^a	57	86	0.007
ED^a	61	46
EGFR (n)^a
Negative	90	112	0.086
Positive	28	20
KRAS (n)^a
Negative	107	127	0.074
Positive	11	5
Chemotherapeutic response (n)
Response	12	126	<0.001
Non-response	106	6
Serum PD-L1 (ng/ml)^a	7.6 ± 3.1	6.5 ± 2.7	0.003

^aLD Limited disease, ED Extensive disease, EGFR Epidermal growth factor receptor, KRAS Kirsten rat sarcoma viral oncogene, PD-L1 Programmed death ligand 1

ISSN: 1465-993X